{
    "Trade/Device Name(s)": [
        "ADVIA\u00ae Chemistry Glucose Hexokinase_3 (GLUH_3) reagent",
        "ADVIA\u00ae Chemistry GLUH_3 Reagent"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K120681",
    "Predicate Device Reference 510(k) Number(s)": [
        "K101854"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "March 2, 2012",
    "Summary Letter Received Date": "March 6, 2012",
    "Submission Date": "May 10, 2012",
    "Regulation Number(s)": [
        "21CFR862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [
        "Li-Heparin tube",
        "K-EDTA tube",
        "Na-Fluoride/K-Oxalate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Chemistry systems"
    ],
    "Method(s)/Technology(ies)": [
        "Hexokinase enzymatic assay"
    ],
    "Methodologies": [
        "Spectrophotometric measurement",
        "Enzymatic reaction"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Chemistry Glucose Hexokinase_3 (GLUH_3) reagent for quantitative glucose measurement using hexokinase enzymatic method on ADVIA Chemistry systems",
    "Indications for Use Summary": "For in vitro diagnostic quantitative determination of glucose in human serum, plasma, urine, and CSF on ADVIA Chemistry systems for diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and insulin overdose",
    "fda_folder": "Clinical Chemistry"
}